TY - JOUR
T1 - Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors
AU - Ghatalia, Pooja
AU - Morgan, Charity J.
AU - Choueiri, Toni K.
AU - Rocha, Pedro
AU - Naik, Gurudatta
AU - Sonpavde, Guru
N1 - Publisher Copyright:
© 2014 Elsevier Ireland Ltd.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - A trial-level meta-analysis was conducted to determine the relative risk (RR) of pancreatitis associated with multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized phase 2 and 3 trials comparing arms with and without an FDA-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, axitinib, vandetanib, cabozantinib, ponatinib, regorafenib). Statistical analyses calculated the RR and 95% confidence intervals (CI). A total of 10,578 patients from 16 phase III trials and 6 phase II trials were selected. The RR for all grade and high-grade pancreatitis for the TKI vs. no TKI- arms was 1.95 (p = 0.042, 95% CI: 1.02 to 3.70) and 1.89 (p=. 0.069, 95% CI: 0.95 to 373), respectively. No differential impact of malignancy type or specific TKI agent was seen on RR of all grade of high grade pancreatitis. Better patient selection and monitoring may mitigate the risk of severe pancreatitis.
AB - A trial-level meta-analysis was conducted to determine the relative risk (RR) of pancreatitis associated with multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized phase 2 and 3 trials comparing arms with and without an FDA-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, axitinib, vandetanib, cabozantinib, ponatinib, regorafenib). Statistical analyses calculated the RR and 95% confidence intervals (CI). A total of 10,578 patients from 16 phase III trials and 6 phase II trials were selected. The RR for all grade and high-grade pancreatitis for the TKI vs. no TKI- arms was 1.95 (p = 0.042, 95% CI: 1.02 to 3.70) and 1.89 (p=. 0.069, 95% CI: 0.95 to 373), respectively. No differential impact of malignancy type or specific TKI agent was seen on RR of all grade of high grade pancreatitis. Better patient selection and monitoring may mitigate the risk of severe pancreatitis.
KW - Approved
KW - Meta-analysis
KW - Pancreatitis
KW - Tyrosine kinase inhibitors
KW - Vascular endothelial growth factor receptor
UR - http://www.scopus.com/inward/record.url?scp=84926122498&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000351794600013&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.critrevonc.2014.11.008
DO - 10.1016/j.critrevonc.2014.11.008
M3 - Review article
C2 - 25541349
SN - 1040-8428
VL - 94
SP - 136
EP - 145
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 1
ER -